CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

NCT07519187 ↗

Phase 0 Recruiting 20 enrolled The General Hospital of Western Theater Command

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.

Timeline

Start: 2026-04-23
Primary completion: 2027-04-01
Completion: 2028-04-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR 70-BCMA CAR-T	Unknown	—	Intravenous

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Summary

Timeline

Drugs

Indications